Health
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
By Marcus Chen
KFGO
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Up nextNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinibHealth · 1 min read
More Health stories
Health
‘Taken far too soon:’ Family remembers Hunter Russey after police say business owner hits, kills teen in West Melbourne
By Marcus Chen
ClickOrlando Local
Business
My spouse was awarded $90,000 from my 401(k) in our divorce. How is that fair?
By Katherine Langford
MarketWatch
Business
‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?
By Katherine Langford
MarketWatch